The Gynecologic Oncology Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber is a leader in research and care for patients with gynecologic cancer, including ovarian cancer, endometrial/uterine cancer, cervical cancer, vulvar cancer, and vaginal cancers, as well as gestational trophoblastic disease. We offer a seamless blend of medical, surgical, radiation, and pathology expertise and develop personalized approaches based on each patient’s specific type of cancer, whether it is early-stage or advanced. Our physicians focus exclusively on the diagnosis and treatment of gynecologic cancers. As one of the world's leading centers for cancer treatment and research, we're able to offer diagnostic tests and therapies based on the most up-to-date scientific findings, including the latest clinical trials.
Featured Items |view more
Antibody-Drug Conjugates: A Cancer Therapy Revolution
Dana-Farber researchers explore how a novel therapy may benefit patients
Researchers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz have found a way to detect increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, according ...
Institute Research Shines at Society of Gynecologic Oncology Annual Meeting
Researchers in the Division of Gynecologic Oncology reported results from an array of clinical trials, gave an overview of trials currently under way, and presented promising findings from the lab.
Seeking Signs of Synergy: The Origins of PARP and PI3K Inhibitors
Pairing multiple drugs together to synergistically destroy a patient's tumor has become a common approach to cancer treatment
Follow-up results of a clinical trial that defined the standard treatment for patients with small, HER2-positive breast cancer that hasn't spread to the lymph nodes reinforce the long-term effectiveness of the therapy.
Dana-Farber Research Supports FDA Approval of New Therapy for Certain Patients with Ovarian Cancer
A novel antibody drug conjugate therapy whose clinical trial testing has been co-led by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November ...